|
|---|
|
Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH
Tuesday, Dec 9, 2008
|
|
| |
CHESHIRE, Conn., Dec 09, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Soliris(R) (eculizumab),
a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc.
(Nasdaq: ALXN), was observed by investigators to reduce blood measures
associated with undiagnosed blood clots and inflammation in patients with PNH.
A separate study...
|
|
|
Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
Monday, Dec 8, 2008
|
|
| |
CHESHIRE, Conn., Dec 08, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals,
Inc. (Nasdaq: ALXN) today reported positive results from AEGIS, an open-label
registration study examining Soliris(R) (eculizumab) treatment of Japanese
patients with paroxysmal nocturnal hemoglobinuria (PNH). The pre-specified
primary effic...
|
|
|
First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting
Sunday, Dec 7, 2008
|
|
| |
CHESHIRE, Conn., Dec 07, 2008 /PRNewswire via COMTEX News Network/ -- CHESHIRE, Conn., Dec. 7 /PRNewswire-FirstCall/-- Soliris(R) (eculizumab),
a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc.
(Nasdaq: ALXN) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH),
was associated with an improvement in hematologic...
|
|
|
Alexion to Present at the 20th Annual Piper Jaffray Health Care Conference
Tuesday, Nov 25, 2008
|
|
| |
CHESHIRE, Conn., Nov 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the 20th Annual Piper Jaffray Health Care Conference in New York City at 10:00 a.m. ET on Tuesday, December 2, 2008.
...
|
|
|
David W. Keiser to Retire as President of Alexion
Tuesday, Nov 11, 2008
|
|
| |
CHESHIRE, Conn., Nov 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Co-Founder Remains On Board Of Directors
Alexion Pharmaceuticals, Inc. ("Alexion," the "Company," Nasdaq: ALXN) announced today that David W. Keiser, the Company's Chief Operating Officer since 1992 and President since 2002, will retire by the end of 2008. Mr. Keise...
|
|
|
Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of PNH at the ASH Annual Meeting
Monday, Nov 10, 2008
|
|
| |
CHESHIRE, Conn., Nov 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Initial Physician Experience with Eculizumab in Patients with Other Rare Complement-Mediated Diseases also to be Presented
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the American Society of Hematology (ASH) has published additional data relati...
|
|
|
Alexion to Present at Investor Conferences
Tuesday, Nov 4, 2008
|
|
| |
CHESHIRE, Conn., Nov 04, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Leonard Bell, M.D., Chief Executive Officer of Alexion Pharmaceuticals, will present at two upcoming investor conferences, one sponsored by Deutsche Bank and the other by Credit Suisse.
Dr. Bell will ...
|
|
|
Alexion Reports Third Quarter 2008 Results
Thursday, Oct 23, 2008
|
|
| |
CHESHIRE, Conn., Oct 23, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Continued Strong Uptake of Soliris(R) in U.S. and Europe
Reported Net Sales of $76.5 Million Include Recognition of $5.3 Million for Prior Quarter Shipments
Company Revises Revenue Guidance Upward and Expense Guidance Downward, and Forecasts GAAP Profit in Full ...
|
|
|
Alexion Pharmaceuticals Invites You to Participate in its Third Quarter 2008 Results Conference Call and Web Cast
Wednesday, Oct 8, 2008
|
|
| |
CHESIRE, Conn., Oct 08, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), today announced that the Company will conduct a conference call and audio web cast on Thursday, October 23, 2008, at 10:00 a.m. Eastern Time (ET), in conjunction with the release of its financial results for the third quarter...
|
|
|
Alexion's Soliris® Receives 2008 Prix Galien USA Award for Best Biotechnology Product
Thursday, Sep 25, 2008
|
|
| |
Cheshire, CT, September 25, 2008 - Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) has received a Prix Galien USA 2008 Award for Best Biotechnology Product for Soliris® (eculizumab). The Award recognizes the scientific innovation represented by the complement-inhibition technology of Soliris, and the impact the drug is having on th...
|
|
|
Alexion to Present at the UBS Global Life Sciences Conference
Tuesday, Sep 16, 2008
|
|
| |
CHESHIRE, Conn., Sept 16, 2008 /PRNewswire via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the UBS Global Life Sciences Conference in New York City at 4:30 p.m. ET on Tuesday, September 23, 2008.
An audio webcast o...
|
|
|
Alexion to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Tuesday, Sep 2, 2008
|
|
| |
CHESHIRE, Conn., Sept 02, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the Morgan Stanley Global Healthcare Unplugged Conference in New York City at 9:45 a.m. ET on Tuesday, September 9, 2...
|
|
|
Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
Thursday, Aug 7, 2008
|
|
| |
CHESHIRE, Conn., Aug 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the U.S. Patent and Trademark Office has issued Patent Number 7,408,041 titled, "Polypeptides and Antibodies Derived from Chronic Lymphocytic Leukemia Cells and Uses Thereof." The patent is assigned to Al...
|
|
|
Alexion Reports Second Quarter 2008 Results
Tuesday, Jul 29, 2008
|
|
| |
CHESHIRE, Conn., July 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Continued Strong Uptake of Soliris(R) in U.S. and Europe
First GAAP Profit; Sales Guidance Revised Upward
Two-For-One Stock Split Announced
Oncology and Kidney Transplantation Clinical Studies Progress
...
|
|
|
Alexion Pharmaceuticals Invites You to Participate in its Second Quarter 2008 Results Conference Call and Web Cast
Thursday, Jul 10, 2008
|
|
| |
CHESHIRE, Conn., July 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), today announced that the Company will conduct a conference call and audio web cast on Tuesday, July 29, 2008, at 10:00 a.m. Eastern Time (ET), in conjunction with the release of its financial results for the second quarter ...
|
|
|
Alexion to Present at the Jefferies & Co. 2nd Annual Healthcare Conference
Wednesday, Jun 18, 2008
|
|
| |
CHESHIRE, Conn., June 18, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the Jefferies & Co. 2nd Annual Healthcare Conference in New York City at 4:15 p.m., ET on Wednesday, June 25, 200...
|
|
|
Soliris(R) Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis
Sunday, Jun 15, 2008
|
|
| |
CHESHIRE, Conn., June 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Soliris(R) (eculizumab) therapy improved the often disabling fatigue experienced by patients with the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH) independent of improvements in anemia, according to data presented today at the European Hematology Assoc...
|
|
|
Alexion to Present at the William Blair 28th Annual Growth Stock Conference
Friday, Jun 13, 2008
|
|
| |
CHESHIRE, Conn., June 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Vikas Sinha, Senior Vice President and Chief Financial Officer of Alexion Pharmaceuticals, will present at the William Blair 28th Annual Growth Stock Conference in Chicago at 9:10 a.m., local time (10:10...
|
|
|
Alexion to Present at the Goldman Sachs 29th Annual Global Healthcare Conference
Thursday, Jun 5, 2008
|
|
| |
CHESHIRE, Conn., June 5, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the Goldman Sachs 29th Annual Global Healthcare Conference in Laguna Niguel, CA at 8:00 a.m., local time (11:00 a.m., ...
|
|
|
Alexion to Present at Citi's 2008 Healthcare Conference
Wednesday, May 14, 2008
|
|
| |
CHESHIRE, Conn., May 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at Citi's 2008 Healthcare Conference in New York City at 4:00 p.m. ET on Wednesday, May 21, 2008.
An audio webcast of...
|
|
|